Title : Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.

Pub. Date : 2015 Jul 23

PMID : 25752494






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 METHODS: Of the 3,316 patients in the J-BENEFIT study, 2,116 not treated with other lipid-lowering drugs were enrolled in the current study, and the effects of 24-week treatment with bezafibrate on the LDL-C levels were analyzed. Bezafibrate component of oligomeric golgi complex 2 Homo sapiens
2 A multivariate logistic-regression analysis of the data for the patients with an LDL-C of >= 25% identified a female sex, the use of anti-hypertensive and hypoglycemic agents and a high baseline LDL-C level to be significant determinants of the LDL-C response to bezafibrate. Bezafibrate component of oligomeric golgi complex 2 Homo sapiens
3 A multivariate logistic-regression analysis of the data for the patients with an LDL-C of >= 25% identified a female sex, the use of anti-hypertensive and hypoglycemic agents and a high baseline LDL-C level to be significant determinants of the LDL-C response to bezafibrate. Bezafibrate component of oligomeric golgi complex 2 Homo sapiens
4 A multivariate logistic-regression analysis of the data for the patients with an LDL-C of >= 25% identified a female sex, the use of anti-hypertensive and hypoglycemic agents and a high baseline LDL-C level to be significant determinants of the LDL-C response to bezafibrate. Bezafibrate component of oligomeric golgi complex 2 Homo sapiens